Pharmafile Logo
Pharmafocus logo
Advanced Search

bladder cancer

Showing 15 posts of 34 posts found.

images

NICE rejects Keytruda for routine use in NHS bladder cancer treatment

November 27, 2019
Research and Development Cancer Drugs Fund, bladder cancer, cancer research

The National Institute for Health and Care Excellence (NICE) has given an initial ‘no’ for Keytruda’s (pembrolizumab) use in treating …

News

Roche’s Tecentriq meets primary endpoint in Phase 3 bladder cancer trial

August 5, 2019
Sales and Marketing Cancer, Roche, bladder cancer, immunotherapy, oncology, tecentriq

Roche has said its immunotherapy drug Tecentriq (Atezolizumab), when used in combination with platinum-based chemotherapy, significantly reduced the risk of …

News

Scientists use cold virus to treat bladder cancer

July 5, 2019
Medical Communications, Research and Development CVA21, Cancer, bladder cancer, oncology, oncolytic, pharma, virus

A strain of the virus that causes the common cold has been found to potentially target, infect and kill cancer …

News
janssen_latest_logo_on_sign_closer

Janssen’s Balversa becomes first FDA-approved FGFR kinase inhibitor for advanced bladder cancer

April 15, 2019
Sales and Marketing Balversa, Cancer, FDA, Janssen, bladder cancer, pharma

Janssen’s Balversa (erdafitinib) has become the first FDA-approved fibroblast growth factor receptor (FGFR) kinase inhibitor after the US agency authorised …

News

Clovis Oncology discontinue phase 2 bladder cancer trial

April 15, 2019
Sales and Marketing Cancer, Clovis Oncology, US, bladder cancer, metastatic bladder cancer

Colorado-based pharma firm Clovis Oncology has said in a filing to the US Securities and Exchange Commission that it is …

News
shutterstock_206748499

17,000 English patients are surviving Stage 4 cancer for two years or more, new data shows

November 8, 2017
Research and Development Cancer, bladder cancer, breast cancer, colon cancer, lung cancer, pharma, prostate cancer

At least 17,000 people in the UK are living with Stage 4 cancer and have survived for two years or …

News
roche

Roche’s Tecentriq scores approvals in metastatic lung and bladder cancer

September 27, 2017
Research and Development, Sales and Marketing Cancer, EMA, EU, European Commission, Roche, bladder cancer, immunotherapy, lung cancer, pharma, tecentriq

It’s good news for Roche as the company’s immunotherapy drug Tecentriq secures approval from the European Commission to be used …

News

Lilly’s Cyramza combo boasts strong results in bladder cancer

September 11, 2017
Research and Development, Sales and Marketing Eli Lilly, bladder cancer, cyramza, immunotherapy, pharma

Eli Lilly has announced new Phase 3 data at the European Society for Medical Oncology 2017 Congress which further add …

News

BMS’ Opdivo scores eighth approval in Europe for bladder cancer

June 5, 2017
Research and Development, Sales and Marketing Bristol-Myers Squibb, Cancer, Europe, European Commission, bladder cancer, immunotherapy

Bristol-Myers Squibb has announced that its flagship immunotherapy treatment Opdivo (nivolumab) has secured its eighth approval in Europe as the …

News
astrazeneca_sign_sky

Potential blockbuster AZ immunotherapy secures FDA approval

May 2, 2017
Manufacturing and Production, Sales and Marketing AstraZeneca, bladder cancer, darzalex

The FDA has granted accelerated approval to AstraZeneca’s (AZ) immunotherapy therapy Imfinzi (durvalumab) for the treatment of locally advanced or …

News

FDA clears Opdivo to treat most common form of bladder cancer

February 6, 2017
Sales and Marketing BMS, Bristol-Myers Squibb, MSD, bladder cancer, immunotherapy, keytruda, opdivo

Bristol-Myers Squibb’s Opdivo has acquired another indication – being given the go-ahead for treatment of patients with metastatic urothelial carcinoma. …

News
roche

Roche’s Tecentriq scores another bladder cancer Priority Review

January 9, 2017
Sales and Marketing Roche, bladder cancer, tecentriq

Roche has announced that its immunotherapy drug Tecenetriq (atezolizumab) has been awarded Priority Review by the FDA for the treatment …

News

Bristol-Myers Squibb’s Opdivo gets US FDA breakthrough therapy designation for advanced bladder cancer

June 28, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Breakthrough Therapy Designation, Bristol-Myers Squibb, FDA, bladder cancer, opdivo, regulation

Bristol-Myers Squibb (NYSE:BMY) said the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to its immunotherapy Opdivo for the …

News
rocheshanghai

FDA grants accelerated approval for Roche’s bladder cancer immunotherapy Tecentriq

May 19, 2016
Research and Development, Sales and Marketing FDA, Roche, atezolizumab, bladder cancer, immunotherapy, tecentriq

Roche (SIX: RO) has announced that the US Food and Drug Administration (FDA) has granted accelerated approval for Tecentriq (atezolizumab) …

News

Genentech cancer immunotherapy gets Priority FDA Review in bladder cancer

March 15, 2016
Manufacturing and Production, Research and Development FDA, Genentech, Roche, atezolizumab, bladder cancer, priority review

The US FDA has granted Roche subsidiary Genentech a Priority Review for atezolizumab in treating advanced bladder cancer, whose disease …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025